Budget Impact of Vericiguat for Treating Chronic Heart Failure in Japan
This analysis highlighted the minimal budgetary impact of vericiguat and its potential to reduce hospitalizations in Japan. Although drug and monitoring costs increased, reductions in acute care expenses helped offset these costs. Further research is needed on long-term cost-effectiveness and real-world outcomes.
Authors
- T. Tsuchiya (ORCID: https://orcid.org/0000-0003-0096-4275)
- Koichiro Kuwahara (ORCID: https://orcid.org/0000-0003-2670-7170)
- You Won Seong
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Yusuke Nakamura
- Russell R. Miller
Institutions
- Shinshu University (JP)
- Syneos Health (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Yakut Scientific Research Institute of Agriculture (RU)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Circulation Reports
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1253/circrep.cr-25-0123
- Primary Topic
- Pharmacy and Medical Practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer Yakuhin